New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareGHK-Cu vs Pancragen

GHK-Cu vs Pancragen

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticRecovery & RepairAnti-Aging & Longevity
GHK-Cu
Anti-Aging & Longevity
Pancragen
Summary
GHK-Cu is a naturally occurring copper complex that declines with age. It is one of the most studied anti-aging peptides, known for powerful skin rejuvenation, wound healing, and tissue remodeling effects.
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Half-Life
2–4 hours
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ, Topical
SubQ, Oral
Research
Typical Dose
1–3 mg
10 mg per day
Frequency
3–5 times per week
Daily for 10–30 days
Key Benefits
  • Reduces wrinkles and fine lines
  • Improves skin firmness and elasticity
  • Accelerates wound healing
  • Reduces inflammation and oxidative damage
  • Promotes hair growth and thickness
  • Supports collagen and elastin production
  • May improve overall skin health and appearance
  • Resets aged fibroblast behavior
  • Anti-fibrotic — reduces scar tissue formation
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
Side Effects
  • Temporary blue-green discoloration at injection site (from copper — harmless)
  • Post-injection sting (brief)
  • Skin irritation with topical use (rare)
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
Stacks With